Gabriel Vidal, MD
Radiation Oncology · Oklahoma City, OKNPI 1487032116
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Novocure Inc. at 32.0% of the total. 2025 is the largest year on record at $420, 4.9 times the $86 reported in 2021. That places this record below the midpoint for radiation oncology clinicians in OK, where the typical reported total is $823.
Across 25 payments — averaging $33.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novocure Inc.$267
- Elekta, Inc.$86
- Novartis$65
- Regeneron Healthcare Solutions, Inc.$51
- Organogenesis Inc.$47
- Kyowa Kirin, Inc.$47
- plus $272 from 11 others
Across 11 payments — averaging $2585.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Microvention, Inc.$28K
What the payments were for
- Travel & lodging$61%
- Food & beverage$82999%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novocure Inc. | 3 | $267 |
| Elekta, Inc. | 1 | $86 |
| Novartis | 3 | $65 |
| Regeneron Healthcare Solutions, Inc. | 2 | $51 |
| Organogenesis Inc. | 1 | $47 |
| Kyowa Kirin, Inc. | 2 | $47 |
| Daiichi Sankyo Inc. | 2 | $45 |
| AstraZeneca | 2 | $42 |
| Globus Medical | 1 | $34 |
| Pfizer | 1 | $21 |
| Caris MPI, Inc. | 1 | $21 |
| Stemline Therapeutics Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $19 |
| Karyopharm Therapeutics Inc. | 1 | $19 |
| Merck | 1 | $18 |
| Incyte Corporation | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NovoTTF-100L$261
How this compares
$835 in reported general payments places this provider in the 50th percentile of 43 radiation oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SsdSilver Sulfadiazine | 30 | $589 |
| Silver Sulfadiazine | 14 | $156 |
| Pantoprazole Sodium | 19 | $120 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Oklahoma City
- Jerry JaboinOklahoma City$14K
- Christina HensonOklahoma City$9K
- Kiran PrabhuOklahoma City$7K
- Tyler GunterOklahoma City$3K
- Mark McLaughlinOklahoma City$3K
- Shripal BhavsarOklahoma City$3K
- Leslie YonemotoOklahoma City$3K
- Gary LarsonOklahoma City$2K
- Andrea JohnstonOklahoma City$2K
- Michael ConferOklahoma City$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.